Assessing the global burden of hemorrhage: The global blood supply, deficits, and potential solutions

Nakul P. Raykar1,2*, Jennifer Makin3, Monty Khajanchi4, Bernard Olayo5, Alejandro Munoz Valencia6, Nobhojit Roy7,8, Pablo Ottolino9, Analia Zinco9, Jana MacLeod6,10, Mark Yazer11, Jayant Rajgopal12, Bo Zeng12, Hyo Kyung Lee12, Bopaya Bidanda12, Pratap Kumar10, Juan Carlos Puyana6 and Kristina Rudd13

Abstract

There is a critical shortage of blood available for transfusion in many low- and middle-income countries. The consequences of this scarcity are dire, resulting in uncounted morbidity and mortality from trauma, obstetric hemorrhage, and pediatric anemias, among numerous other conditions. The process of collecting blood from a donor to administering it to a patient involves many facets from donor availability to blood processing to blood delivery. Each step faces particular challenges in low- and middle-income countries. Optimizing existing strategies and introducing new approaches will be imperative to ensure a safe and sufficient blood supply worldwide.

Keywords

Global blood availability, blood transfusion, global surgery, walking blood banks, unbanked directed blood transfusion

Introduction

Hundreds of millions of people experience traumatic injury, obstetric bleeding, and pediatric anemias each year and require immediate access to blood transfusion.1,2 Hemorrhage is responsible for the majority of deaths of trauma patients who do not reach the hospital, and up to 40% of deaths of those who do.3,4 Postpartum hemorrhage (PPH) is the most common cause of maternal mortality, responsible for up to 35% of maternal deaths.5 Some estimates suggest that up to 6% of all pregnant women will experience some amount of PPH.5 In addition, anemias in the pediatric and adult populations from malaria, sickle cell trait, and cancer frequently require blood for treatment.6,7

For clinicians in some high-income countries (HICs), administering a blood transfusion to a bleeding patient is relatively straightforward: an order is placed and the blood bank sends blood. For the majority of clinicians and patients in low- and middle-income countries (LMICs), however, obtaining blood for transfusion is not a guarantee. Blood collection rates vary dramatically worldwide;8 117 million units of blood are collected annually, but half of this volume comes from just four regions, which account for just 20% of the world’s population: the United States (US), Canada, Europe, and Australia.9 This leaves LMICs with an unmet need totaling over 100 million units each year. A total of 61%
of countries—including every country in sub-Saharan Africa, South Asia, and Oceana—have blood shortages.

In this narrative review, we outline the complex process of blood transfusion and draw attention to the unique challenges to this process in the world’s poorest settings. We then highlight some approaches to improve blood availability. We use the term “LMIC” and “low-resource setting” synonymously for the purpose of this review, though we recognize that low-resource settings are not restricted to LMICs, just as adequate resources are not restricted to HICs.

The blood transfusion continuum
Safe transfusion of blood depends on a system of interconnected steps, from population health to adverse event monitoring, each relying on infrastructure, logistics, human resources, and financial capital. This continuum of blood transfusion can be broadly grouped into blood availability, processing, and delivery (Figure 1).

Blood availability
The blood transfusion process starts with collecting blood from suitable donors. Collection organizations advertise to recruit new and repeat blood donors through direct contact, community organizations, and social media. Most organizations collect through clinics and hospitals as well as mobile donation drives and camps. It is important that blood collection organizations collect adequate quantities of blood from healthy donors with low risk of harboring transfusion transmissible illness (TTI). Donor screening questionnaires are employed to identify those with major risk factors. Ideally, the donor voluntarily provides blood without financial reward, also known as voluntary, non-remunerated blood donation (VNRD).

Blood processing
Collected blood is tested for blood type (A, B, AB, O) and for TTIs based on local disease prevalence and international consensus standards. In the US, for example, blood is routinely tested for hepatitis B virus (HBV), human immunodeficiency virus (HIV), human T-leukemia virus, and hepatitis C virus (HCV). Testing for malaria is based largely on travel history. Additional testing for Babesia, Chikungunya, dengue, Zika virus, West Nile virus, and hepatitis E virus is based on specific risk factors and seasonal and regional prevalence. In much of South and Central America, testing for Trypanosoma cruzi (Chagas disease) is standard, and many sub-Saharan African and South Asian centers test for malaria.

Most blood banks split whole blood into its components: specifically red blood cells, plasma, and platelets. While there is renewed interest in whole blood transfusion in many high-resource settings for the management of acute bleeding, componentization of blood can improve efficiency by allowing targeted transfusion of necessary blood components, avoiding volume overload with smaller volume transfusions, and improving shelf life and ease of storage of some components. Platelets, for example, can remain at room temperature, while packed red blood cells, plasma, and stored whole blood are refrigerated at 1°C–6°C.
Table 1. Common challenges to the blood transfusion continuum in LMICs across the domains of availability, testing and processing, and delivery.

| Blood availability                                  | Blood testing and processing                                      | Blood delivery                                                   |
|-----------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------|
| • High baseline anemia                              | • High rates of transfusion, transmissible infection, and        | • High rates of wastage due to logistical and transport issues   |
| • High rates of HBV, HCV, HIV, and malaria           | transmission Inconsistent testing                                | Rare hospital-level transfusion policies                        |
| • High donor deferral and poor follow-up            | • Variability in blood testing strategies                        | and quality improvement programs                                 |
| • Distrust of blood donation                         | • Poor availability of tests with high sensitivity and specificity| Inappropriate use of available blood                             |
| • Paid and replacement donation predominate         |                                                                  |                                                                 |

HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus.

Blood delivery

Depending on the regional arrangements, blood can either be collected and transfused to patients locally or collected centrally and then distributed to peripheral hospitals and clinics that lack blood banks. Prior to transfusion, the recipient’s blood is tested for ABO and Rh types and screened for significant non-ABO antibodies. Patient blood must be additionally crossmatched with the donor blood either physically or with computer algorithms as appropriate. Institutional, regional, and/or national guidelines often guide transfusion processes as well as decisions on whom to transfuse, and how to address and monitor for adverse reactions. Adverse events are carefully tracked and occurrences are reported to the blood bank in a quality assurance process.

Challenges to the blood transfusion process in low-resource settings

The process of safe blood transfusion is logistically complex and resource-intensive. LMICs face multiple challenges with respect to each step in the blood transfusion continuum, from blood availability to processing to delivery (Table 1).

Challenges with blood availability

Poor population health from inadequate nutrition and chronic anemia are pervasive. The World Health Organization (WHO) suggests blood donors should have a minimum hemoglobin of 13 g/dL in men and 12 g/dL in women. Unfortunately, over 40% of all individuals in LMICs are estimated to be anemic, with a staggering predominance in the lower socioeconomic groups. This presents multiple unique challenges to blood collection in LMICs. First, it heightens the need for blood availability should these individuals fall ill, while simultaneously disqualifying much of the population from blood donation. Second, anemia itself may predispose women to more bleeding complications. Baseline anemia may be associated with up to a 30% increased risk of PPH.

High rates of TTIs such as HBV, HCV, and HIV in many LMICs further erode an already diminished donor pool. While not reflective of nationwide rates of infection, certain regions of Tanzania, Kenya, Pakistan, and Nigeria have previously demonstrated seroprevalence rates as high as 37% for HBV, 40% for HCV, 30% for HIV, and 50% for malaria.

An added consequence of widespread anemia and infection is a high rate of blood donors deferred from donation. A center in Nigeria reported turning away over 30% of volunteers due to poor health, nearly three times rates in some HICs. Donor deferrals impose a cost burden on blood collection efforts and serve as significant negative motivators for volunteers. Importantly, 75% of deferred donors do not return for blood donation, even if they would be eligible at a later time.

Distrust of the blood collection system among potential blood donors further lowers collections. In some parts of sub-Saharan Africa, concerns persist due to a shameful history of forced blood donation of Africans for colonist benefit. Concerns about the health risks of blood donation, some justified while others stem from misinformation, also serve as potent disincentives.

While the ideal blood donor is an adult acting voluntarily and without financial motivation, as the size of the eligible donor pool narrows, blood banks in LMICs frequently depend on paid or replacement donations, or particular donor populations. Paid donors are monetarily compensated for donation, while replacement donors are typically family members or friends who donate in order to “replace” blood units to a blood bank that has provided blood to the patient. This presents unique logistical and ethical challenges, as oftentimes the patient is denied transfusion until a family member has donated blood, and family members are also often anemic and unfit for blood donation. Paid donation has been associated with safety risks from over-donation under expanded criteria. Avoiding both paid and replacement donors, many blood collection organizations rely on school-aged children to form the majority of the donor pool. In addition to ethical challenges, this leads to dramatic blood shortages when school is out of session.

Challenges with blood processing

The risk of infectious disease transmission through blood transfusion is small in HICs, but remains a threat in
Investment in professionalized blood donor services

Judicious use of non-financial incentives, including blood credits

Mobile blood donation drives to reduce geographic barriers

Active, coordinated community engagement through public service announcements, use of traditional media and social media, celebrities, community, and religious organizations

Mobile blood donation drives to reduce geographic barriers

Judicious use of non-financial incentives, including blood credits

Investment in professionalized blood donor recruitment services

Nutritional and iron supplementation

HIV, 4,300 units with HBV, and 2,500 with HCV. Accounting for the rates of transfusion, the authors estimated the combined number of new HIV, HBV, and HCV infections in 2010 from blood transfusions in LMICs to be 51,870 per year.

A closer look at the testing process provides some explanation for higher rates of transmission. Most HIC blood systems employ a coordinated testing strategy with high rates of sensitivities for HIV, HBV, and HCV in the range of 95%–99%. A study at six major African blood centers demonstrated heavy reliance on early generation rapid diagnostic testing (RDT) kits, some of which have a sensitivity of under 50% for the hepatitis viruses. Not all RDTs performed poorly, however, and the overall testing quality across centers was relatively high. In areas with high disease prevalence, though, even tests with high sensitivities will miss infection. As such, the WHO recommends a dual-stage minimum testing process, combining RDT kits with an enzyme-linked immunosorbent assay (ELISA) or nucleic acid test. In a survey of blood centers in seven African countries, researchers found that only two employed dual-stage testing. Newer generation RDTs can be highly sensitive and specific—rivaling ELISA—but availability and usage is variable.

Challenges with blood delivery

After successful collection and testing of blood, administration of blood to the recipient depends on adequate human resources powered by appropriate infrastructure and organized logistics. National and regional governmental policies can promote organization by coordinating testing strategies and adherence, centralizing resources, and developing mechanisms for donor tracking, engagement, and infection follow-up. According to a 2009 WHO report and a 2013 Pan American Health Organization report, the prevalence of national policies governing blood transfusion systems ranged from 54% (Central and South Americas) to 77% (Europe).

At the blood collection stage, the absence of coordination between blood banking organizations can lead to aggressive competition for the same pool of donors—multiple organizations attempting to collect from the same local college, for example—instead of a systematic effort to expand the donor pool. In the testing and delivery phases, absence of harmonization promotes inconsistent refrigeration and challenges with blood storage, difficulties in processing and transportation to and from remote blood centers, data entry errors, and high rates of expiration and wastage. A survey of sub-Saharan African blood bank systems found few personnel with training in transfusion medicine, and few had transfusion committees overseeing blood transfusion across the system.

In the absence of standardized transfusion policies and oversight, scarce available blood is often inappropriately over- or under-utilized. Transfusion hemoglobin targets of 10 g/dL persist in some settings, despite high-quality scientific evidence that a target of 7 g/dL is sufficient for most patients. In a multi-institution analysis in Tanzania, researchers found an “inappropriate” transfusion rate of 17%–32% within one health system. In addition to poor adherence to guidelines driving inappropriate transfusion, clinician tactics to circumvent chronic shortages such as ordering blood in greater quantities than necessary for fear of it running out, also contributes to wastage.

Addressing the global blood deficit

Strengthening blood systems will require a coordinated, multifaceted approach that both optimizes time-tested recommendations and explores techniques that are both disruptive and innovative, appropriate for local contexts (Table 2).
Increase donor availability

Increasing the number of potential donors starts with improving the baseline population health. Nutritional supplementation and iron replacement regimens have been shown to decrease rates of anemia. Context-specific innovation is required to specifically combat reasons for non-adherence to regimens such as unavailability of supplements, poor provider training on explaining need for supplementation, and misconceptions of side effects.45,46

Potential donors can be actively recruited through aggressive public service advertising, community health worker outreach, and blood donation drives. While there are many reasons individuals do not donate, in many instances the most common reason is “nobody asked.”27,47 Television advertisements and programs, including public service announcements with celebrities, are effective in encouraging donation. More recently, social media and innovative mobile health applications have emerged as high-value tools to raise awareness and mobilize donors.48,49

Even in settings where healthcare facilities are easy to access, few will make a trip to donate blood.50 Mobile donation sites in high-traffic areas and through outreach efforts not only reduce geographic barriers to donation but can also serve to educate the public about blood donation and have a record of success across high-income settings.51

Purposeful engagement of communities and religious organizations can be effective. Religious altruism is an important motivator of blood donation in some HICs, and in New Delhi and its surrounding areas in northern India over 70% of voluntary donation comes from members of religious organizations.52,53

Judicious use of non-financial incentives that drive replacement donation in low-resource settings may also help to augment the donor pool. In one study, half of the potential donors reported increased likelihood to donate blood for future assurance of blood for themselves or their direct family members.26,54 Blood credits, where individuals who donate are assured future access to transfusion at reduced cost, have shown promise, especially when focusing on groups with higher-than-average blood needs such as taxi drivers or pregnant women. Blood credit programs, however, can be logistically challenging to implement and evaluations of formal, large-scale programs featuring blood credits are lacking.55

Regardless of the specific method used, research shows that interventions are most effective when they target social awareness, exploit altruistic motivations, and involve direct, in-person contact.56 Active engagement through follow-up phone calls is more effective than passive modalities, including email and free gifts.55,57 This includes efforts to encourage repeat donation, also critical to maintaining the donor pool. While time- and resource-intensive to maintain, donor registries have had success in tracking high-value, low-risk, repeat donors and encouraging donation.58

Improve blood processing

Improved blood safety starts with improved donor screening questionnaires. Donor screening questionnaires are a key modality through which to identify donors at high risk for harboring TTIs—those exposed to high risk activities—that may escape detection in the “window period” due to recent infection by yielding a false negative from the screening test (Figure 2). What constitutes a “high-risk” activity, however,
is not the same in all parts of the world. Developing context-appropriate donor screening questionnaires may be a low-cost intervention with high impact. A 2017 study in Cameroon found many local risk factors for HIV such as polygamy or street-vendor treatment for dental procedures that could replace questions, often adapted from HIC questionnaires with little local relevance. Research is imperative to develop adequate, relevant, and culturally appropriate screening questionnaires.

Nucleic acid testing (NAT) can best mitigate the risk of infection transmission through the blood supply where TTIs are of highest population prevalence, but it is unlikely to be affordable on a large scale throughout LMICs any time soon. NAT dramatically improves detection of window-period infections and reduces false negatives. NAT can reduce the HIV window period by up to 16 days, HCV by up to 65 days, and HBV up to 36 days. In HICs, extremely high costs in the setting of low TTI seroprevalence baselines have led some to question its utility. In LMICs, however, high disease prevalence and first-time donors predominate and the added sensitivity can translate into thousands of cases detected, arguably altering the cost-effectiveness equation. A study of blood centers in India suggested that infection detection using NAT would be 29 times higher than that in Japan, an HIC with low TTI disease prevalence whose blood banks routinely employ NAT. And while individual testing can be cost-prohibitive, innovative methods to pool specimens—testing hundreds of patients simultaneously and performing individual testing only if the pooled sample tests positive—may be effective in bringing down costs. More controversially, some countries like South Africa have used the increased yield of plasma to generate additional revenue from plasma fractionation and sale of plasma products, which has in turn offset a significant portion of the cost of adopting NAT.

While affordable NAT will continue to be elusive for the near future, testing with ELISA will improve detection of false negatives and false positives from RDT. LMICs and funders must work to incorporate this into the testing rubric as soon as possible. The benefits may extend beyond increased blood safety. One study of early generation RDT performance found that only 20% of initially reactive samples were positive on confirmatory testing, and thus regions that rely heavily on RDT for donor screening likely discard a large number of otherwise appropriate blood units.

Finally, RDT, relatively inexpensive and widely available, will likely remain the de facto testing system in much of the world’s poorest settings. Rather than lamenting this reality, decision-makers may seek to optimize this process as newer generation RDTs have enhanced sensitivities and specificities rivaling (and sometimes exceeding) ELISA in the appropriate context. Testing RDTs in LMIC contexts to optimize performance and processes must take priority. Recognizing wide variation in RDT kit performance, government laboratories should verify RDT performance and implement quality assurance and monitoring protocols.

Pathogen inactivating technologies (PITs) offer a potential paradigm shift in blood transfusion safety, transitioning from a reactive approach of identifying and avoiding blood units from infected donors to a proactive approach of treating collected blood and rendering the pathogens harmless. PITs comprise a variety of modalities that expose collected blood to chelating agents and/or ultraviolet (UV) energy. These technologies are available for treatment of plasma and platelets and lead to an exponential reduction of multiple pathogens, including HCV, HIV, HBV, malaria, and syphilis. One system, used in Ghana to treat whole blood, succeeded in reducing the incidence of malaria transmission via blood transfusion from 22% to 4%. A recent modeling study in Uganda found that combining RDT with PIT, versus the current local standard of single-stage ELISA, would reduce infectious units of HIV, HBV, HCV, and malaria by 100%, 20%, 98%, and 83%, respectively. While promising, cost concerns, as well as challenges with blood product loss and immunogenicity of treated products, will need to be addressed with continued development and field testing in a variety of settings. Additional research is urgently needed.

Ultimately, regardless of the specific testing strategy used, gains in blood safety obtained by mandating a more expensive test with improved sensitivity and specificity must be weighed against increased testing costs. Maintaining that the highest standards of blood transfusion testing must be applied in every case regardless of cost or context will lead to uncounted morbidity and mortality from existing and exacerbated blood shortages.

Componentization has many benefits, is a hallmark of HIC transfusion systems, and has been widely adopted in countries that rely heavily on external financial support for their blood systems. On one hand, componentization can enhance the supply by generating multiple products from a fixed quantity of whole blood. On the other hand, componentization in LMICs can increase processing costs and time wastage of individual components, particularly plasma. Furthermore, there is growing recognition all over the world that severe hemorrhagic shock is best treated with whole blood as opposed to components. Thoughtful standards must arise from careful evaluation of the benefits of componentization along with its drawbacks and an understanding of the local blood needs in each regional context.

**Improve blood delivery**

A systematic and coordinated policy approach can positively impact all stages of the blood continuum. Protocols and professionalized blood banking staff are critical components. Multiple transnational organizations, such as the Pan American Health Organization and the Africa Society for Blood Transfusion, offer training and guidance to blood bank staff on all aspects of the blood continuum.
Ultimately, the ability to take tested and processed blood from a blood bank and administer it to the right patient at the right time, while taken for granted in many high-income health systems, requires the coordinated function of multiple individuals from blood banking staff to nurses, physicians, quality improvement/process monitoring personnel, and patients and their family members. A 2019 article by Pirabán et al. provides a comprehensive review of the proposed models and methods for decision making and modeling blood distribution systems (also referred to as blood supply chains). The article presents a taxonomy for categorizing current literature (2005–2019) in blood supply chains and also presents gaps and overlaps in modeling.

Sound policymaking that addresses the multiple ground-level barriers to safe and efficient transfusion should be based on the committed inquiry of all stakeholders. Hospital-based, regional, and national transfusion committees can adopt this work and establish evidence-based guidelines adapting the best of international standards to local needs.

Outside of the traditional paradigm of the blood banking continuum, new technologies and approaches may provide alternative ways to address blood shortages. Novel transportation technology, for example, may provide ways to expand the distribution radius of a blood bank. Many organizations are actively exploring drones as a means to deliver medications and blood into remote areas with challenging geography. One company has combined drones with a mobile app that allows hospitals and physicians to order blood supplies on-demand, with arrival in as little as 30 min. Another expanding area of development is autotransfusion, either in the preoperative or intraoperative setting. Preoperative autologous transfusion, where blood is collected from patients before an operation in preparation for potential blood loss, has had success in sub-Saharan Africa for elective surgery. Emergent options for autotransfusion require different strategies. Collecting lost blood, filtering, and administering it back to the patient as a transfusion has been commonplace in HIC operating rooms during cardiac and spinal surgery since the 1980s. In the face of extreme blood scarcity and significant trauma volume, several authors of this article have collected blood from a chest tube collection cannister and provided it as a blood transfusion. Yet, there are differences between makeshift intraoperative autotransfusion and more sophisticated technologies that wash red cells prior to autotransfusion. Again, more research is urgently needed. Several prototypes are being developed. The Hemafuse device, for example, is a low-cost handheld device that uses manual pump suction instead of electricity and is undergoing clinical trials in Ethiopia (Figure 3).

For the time being, a hospital-based replacement donor strategy will likely need to coexist with a volunteer nonremunerated donor base to meet urgent demand. The pursuit of 100% VNRD, a stalwart of WHO and expert consensus for decades, continues to be a major (and elusive) goal of many LMIC blood systems. Replacement donation is cheaper and more available. Studies that previously argued that replacement donors carry a higher rate of TTI compared with VNRDs have been reevaluated and shown to have significant methodologic flaws, including confounding between first-time and repeat donors. First-time donors do have a higher rate of TTI than recurrent donors, and the studies that showed a higher rate of TTI in replacement donors never controlled for the higher rate of first-time donors in the replacement pool. One ground-up alternative incorporates...
elements of both. Unbanked, directed blood transfusion also
known as “walking blood banks,” works through a network
of prescreened donors in the community available for sum-
mons in an emergency, with an expedited blood testing pro-
cess prior to transfusion.90 The system is designed to function
in austere environments in which patients may need blood
immediately but with low frequency, or which lack local
storage capacity, such as military combat zones.91 In these
military settings, time to fresh whole blood transfusion has
been reported to be as little as 18 min.92 Civilian walking
blood banks (cWBBs) have been used informally since at
least the 1990s in remote settings in India, though formal
study in the civilian sector has yet to be conducted. While
seemingly ideal for civilian use in remote settings, signifi-
cant knowledge gaps exist in the feasibility of establishing
reliable WBBs in the civilian context. More data are needed,
and governments and academic institutions should actively
explore opportunities to perform pilot studies.

This is a narrative literature review. As such, the data
included are subject to the biases associated with narrative
reviews. Nonetheless, given that the review was designed to
highlight a broad range of challenges and solutions across
the continuum of blood transfusion, a systematic review
would not have been appropriate. The authors have clinical
and research experience in low-resource settings and have
attempted to balance perspectives represented in the litera-
ture accurately.

Conclusion

There is a critical shortage of blood in most LMICs, resulting
in increased morbidity and mortality from conditions that
include traumatic injury, obstetric hemorrhage, and anemia.
Safe transfusion of blood depends on an interconnected sys-
tem that spans population health to adverse reaction monitor-
ing, each component relying on infrastructure, logistics,
human resources, and financial capital. Many blood systems
share common challenges in blood availability, processing,
and delivery. Addressing the shortage and appropriate stew-
ardship of scarce resources requires a multifaceted approach
employing traditional best practices, context-appropriate
innovations, and multidisciplinary policymaking through all
levels of the delivery chain from hospitals to national
governments.

Author note

Nakul P. Raykar is now affiliated to Program in Global Surgery and
Social Change, Harvard Medical School, Boston, MA, USA.
Nabhojit Roy is now affiliated to World Health Organization
Collaborating Centre for Research in Surgical Care Delivery in
LMICs, Mumbai, India.

Author contributions

N.P.R. and K.R. designed and wrote the manuscript. M.K., B.O.,
N.R., P.O., A.Z., and J.M. provided critical perspectives based on
firsthand accounts in LMICs in addition to literature review and
writing support. J.M., A.M.V., J.R., B.B., B.Z., and J.C.P. provided
literature review and editing. All authors reviewed the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, author-
ship, and/or publication of this article.

ORCID iDs

Nakul P. Raykar https://orcid.org/0000-0003-1825-7333
Kristina Rudd https://orcid.org/0000-0002-6695-8401

References

1. Vos T, Allen C, Arora M, et al. Global, regional, and national
incidence, prevalence, and years lived with disability for 310
diseases and injuries, 1990–2015: a systematic analysis
for the Global Burden of Disease Study 2015. Lancet 2016;
388(10053): 1545–1602.
2. Roth GA, Abate D, Abate KH, et al. Global, regional, and
national age-sex-specific mortality for 282 causes of death in
195 countries and territories, 1980–2017: a systematic analy-
sis for the Global Burden of Disease Study 2017. Lancet 2018;
392(10159): 1736–1788.
3. Tran N, Breene J, Khayesi M, et al. WHO global status report
on road safety: Report from the World Health Organization.
Geneva: WHO, 2018.
4. Baraniuk S, Tilley BC, del Junco DJ, et al. Pragmatic
Randomized Optimal Platelet and Plasma Ratios (PROPPR)
Trial: design, rationale and implementation. Injury 2014;
45(9): 1287–1295.
5. Ashigbie P and Tanna S. WHO background paper 6.16 on
postpartum haemorrhage: report from the World Health
Organization. Geneva: WHO, 2013.
6. Kiguli S, Maitland K, George EC, et al. Anaemia and blood
transfusion in African children presenting to hospital with
severe febrile illness. BMC Med 2015; 13(1): 21.
7. Scott S, Chen-Edinboro L and Murray-Kolb L. The impact of
anaemia on child mortality. Nutrients 2014; 6(12): 5915–5932.
8. World Health Organization. WHO global status report on
blood safety and availability 2016: report from World Health
Organization. Geneva: WHO, 2017.
9. Roberts N, James S, Delaney M, et al. The global need and
availability of blood products: a modelling study. Lancet
Haematol 2019; 6: E606–E615.
10. Chargé S. Vein to vein: a summary of the blood system in
Canada. Canadian Blood Transfusion Services 2019, https://
professionaleducation.blood.ca/en/transfusion/clinical-guide/
vein-vein-summary-blood-system-canada
11. WHO blood donor selection guidelines on assessing donor
suitability for blood donation: report from the World Health
Organization. Geneva: WHO, 2012.
12. Longo DL, Carson JL, Triulzi DJ, et al. Indications for and
adverse effects of red-cell transfusion. N Engl J Med 2017; 13:
1261–1272.
13. Moncayo Silveira AC. Current epidemiological trends of Chagas disease in Latin America and future challenges: epidemiology, surveillance, and health policies. In: Telleria J and Tibayrenc M (eds) American trypanosomiasis chagas disease: one hundred years of research. 2nd ed. Amsterdam: Elsevier, 2017. pp. 59–88.

14. Field SP and Allain J-P. Transfusion in sub-Saharan Africa: does a Western model fit? J Clin Pathol 2007; 60(10): 1073–1075.

15. Supply of blood for transfusion in Latin American and Caribbean countries 2010 and 2011: report from the Pan American Health Organization. Washington, DC: Pan American Health Organization, 2013.

16. Balarajan Y, Ramakrishnan U, Özaltin E, et al. Anaemia in low-income and middle-income countries. Lancet 2011; 378(8): 2123–2135.

17. Jung J, Rahman M, Rahman S, et al. Effects of hemoglobin levels during pregnancy on adverse maternal and infant outcomes: a systematic review and meta-analysis. Ann N Y Acad Sci 2019; 1450: 69–82.

18. Global health sector strategy on viral hepatitis 2016–2021: report from the World Health Organization. Geneva: WHO, 2016.

19. Tagny C, Diarra A, Yahaya R, et al. The transfusion center, the blood donor and the given blood in francophone African countries. Transfus Clin Biol 2009; 16: 431–438.

20. Owusu-Ofori AK, Parry C and Bates I. Transfusion-transmitted Malaria in countries where Malaria is endemic: a review of the literature from sub-Saharan Africa. Clin Infect Dis 2010; 51: 1192–1198.

21. Agnihotri N. Whole blood donor deferral analysis at a center in Western India. Asian J Transfus Sci 2010; 4: 116–122.

22. Aneke C, Ezeh U, Nwosu A, et al. Retrospective evaluation of prospective blood donor deferral in a tertiary hospital-based blood bank in South-East Nigeria. J Med Tropics 2016; 18: 103–107.

23. Mast AE. Low hemoglobin deferral in blood donors. Transfus Med Rev 2014; 28: 18–22.

24. Smith GA, Fisher SA, Dorée C, et al. A systematic review of factors associated with the deferral of donors failing to meet low haemoglobin thresholds. Transfus Med 2013; 13: 309–320.

25. Geissler PW. “Kachinja are coming!”: encounters around medical research work in a Kenyan village. Afr J Int African Inst 2005; 75: 173–202.

26. Lownik E, Riley E, Konstenius T, et al. Knowledge, attitudes and beliefs of people in North India regarding blood donation. Transfus Med 2016; 53(10 Pt. 2): S21–S27.

27. Bates I, Manyasi G and Medina Lara A. Reducing replacement donors in sub-Saharan Africa: challenges and affordability. Transfus Med 2007; 17: 434–442.

28. Boukouatta G, Boukou mais N, Ngombe S, et al. The transfusion center, the blood donor and the given blood in francophone African countries. Transfus Med Rev 2014; 28: 18–22.

29. Kyeiye-Byabazaire D and Hume HA. Towards a safe and sufficient blood supply in sub-Saharan Africa. ISBT Sci 2019; 14: 104–113.

30. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495–1504.

31. Stramer SL, Notari EP, Krysztof DE, et al. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety. Transfusion 2013; 53(10 Pt. 2): 2449–2458.

32. Jayaraman S, Chalabi Z, Perel P, et al. The risk of transfusion-transmitted infections in sub-Saharan Africa. Transfusion 2010; 50: 443–442.

33. Busch MP, Bloch EM and Kleinman S. Prevention of transfusion-transmitted infections. Blood 2019; 133: 1854–1864.

34. Prugger C, Laperche S, Murphy EL, et al. Screening for transfusion-transmissible infections using rapid diagnostic tests in Africa: a potential hazard to blood safety. Vox Sang 2016; 110: 196–198.

35. Laperche S, Boukouatou G, Kouegnogn L, et al. Transfusion safety on the African continent: an international quality control of virus testing in blood banks. Transfusion 2009; 49: 1600–1608.

36. Guidelines on Hepatitis B and C testing: report from the World Health Organization. Geneva: WHO, 2017.

37. Tagny CT, Diarra A, Yahaya R, et al. Characteristics of blood donors and donated blood in sub-Saharan Francophone Africa. Transfusion 2009; 49: 1592–1599.

38. Developing a national policy and guidelines on the clinical use of blood recommendations: report from the World Health Organization. Geneva: WHO, 2001.

39. Moore A, Herrera G, Nyamongo J, et al. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet 2001; 358: 657–660.

40. Butler EK, Hume H, Birungi I, et al. Blood utilization at a national referral hospital in sub-Saharan Africa. Transfusion 2015; 55(5): 1058–1066.

41. Javazdadeh Shahshahani H and Taghvai N. Blood wastage management in a regional blood transfusion centre. Transfus Med 2017; 27: 348–353.

42. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB. JAMA 2016; 316: 2025–2035.

43. Sood R, Yorlets RR, Raykar NP, et al. The global surgery use of blood recommendations: report from the World Health Organization. Geneva: WHO, 2017.

44. Ndiaye M, Siekmans K, Haddad S, et al. Impact of a positive result on the clinical practice towards blood donation among voluntary blood donors in a tertiary hospital-based blood bank. Transfus Clin Biol 2013; 26: 196–198.

45. Galloway R and McGuire J. Determinants of compliance with iron supplementation: supplies, side effects, or psychology? Soc Sci Med 1994; 39: 381–390.

46. Ndiaye M, Siekmans K, Haddad S, et al. Impact of a positive result on the clinical practice towards blood donation among voluntary blood donors in a tertiary hospital-based blood bank. Transfus Clin Biol 2013; 26: 196–198.

47. Moore A, Herrera G, Nyamongo J, et al. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet 2001; 358: 657–660.

48. Butler EK, Hume H, Birungi I, et al. Blood utilization at a national referral hospital in sub-Saharan Africa. Transfusion 2015; 55(5): 1058–1066.

49. Javazdadeh Shahshahani H and Taghvai N. Blood wastage management in a regional blood transfusion centre. Transfus Med 2017; 27: 348–353.

50. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB. JAMA 2016; 316: 2025–2035.

51. Sood R, Yorlets RR, Raykar NP, et al. The global surgery use of blood recommendations: report from the World Health Organization. Geneva: WHO, 2017.

52. Ndiaye M, Siekmans K, Haddad S, et al. Impact of a positive result on the clinical practice towards blood donation among voluntary blood donors in a tertiary hospital-based blood bank. Transfus Clin Biol 2013; 26: 196–198.

53. Moore A, Herrera G, Nyamongo J, et al. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet 2001; 358: 657–660.

54. Butler EK, Hume H, Birungi I, et al. Blood utilization at a national referral hospital in sub-Saharan Africa. Transfusion 2015; 55(5): 1058–1066.

55. Javazdadeh Shahshahani H and Taghvai N. Blood wastage management in a regional blood transfusion centre. Transfus Med 2017; 27: 348–353.
50. Mews M. To pay or not to pay: the role of monetary incentives in an optimal blood donation service bundle. *Int J Nonp Volunt Sect* 2013; 18: 192–202.

51. Weidmann C, Schneider S, Litaker D, et al. A spatial regression analysis of German community characteristics associated with voluntary non-remunerated blood donor rates. *Vox Sang* 2012; 102: 47–54.

52. Healy K. Embedded altruism: blood collection regimes and the European Union’s donor population. *Am J Sociol* 2000; 105: 1633–1657.

53. Copeman J. Veins of devotion: blood donation and religious experience in North India. New Brunswick, NJ: Rutgers University Press, 2009.

54. Shenga N, Pal R and Sengupta S. Behavior disparities towards blood donation in Sikkim, India. *Asian J Transfus Sci* 2008; 2: 56–60.

55. Chell K, Davison TE, Masser B, et al. A systematic review of incentives in blood donation. *Transfusion* 2018; 58: 242–254.

56. Godin G, Vézina-Im L-A, Bélanger-Gravel A, et al. Efficacy of interventions promoting blood donation: a systematic review. *Transfus Med Rev* 2012; 26: 224.e–237.e.

57. Reich P, Roberts P, Laabs N, et al. A randomized trial of blood donor recruitment strategies. *Transfusion* 2006; 46: 1090–1096.

58. Garbarino E, Heger S, Wang C, et al. Redesigning the market for volunteers: a Donor Registry. *Association for Consumer Research, 2017, http://www.acrwebsite.org/volumes/1023880/volumes/v45/NA-45http://www.copyright.com/*

59. Tagny CT, Nguefack-Tsague G, Fopa D, et al. Risk factors for human immunodeficiency virus among blood donors in Cameroon: evidence for the design of an Africa-specific donor history questionnaire. *Transfusion* 2017; 57: 1912–1921.

60. Makroo RN, Choudhury N, Jagannathan L, et al. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus-1 & hepatitis B & C viruses in Indian blood donors. *Ind J Med Res* 2008; 127: 140–147.

61. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. *Transfusion* 2005; 45: 254–264.

62. Gous N, Scott L, Perovic O, et al. Should South Africa be performing nucleic acid testing on HIV enzyme-linked immunosorbent assay-negative samples. *J Clin Microbiol* 2010; 48: 3407–3409.

63. Jain R, Aggarwal P and Gupta GN. Need for nucleic acid testing in countries with high prevalence of transfusion-transmitted infections. *ISRN Hematol* 2012; 2012; 718671.

64. El Ekiaby M, Lelie N and Allain JP. Nucleic acid testing (NAT) in high prevalence–low resource settings. *Biologicals* 2010; 38: 59–64.

65. Safic Stanic H, Babic I, Maslovic M, et al. Three-year experience in NAT screening of blood donors for transfusion transmitted viruses in Croatia. *Transfus Med Hemonet* 2017; 44: 415–420.

66. Katz LM, Donnelly JJ, Gresens CJ, et al. Report of a workshop on ensuring sustainable access to safe blood in developing countries: International Blood Safety Forum, March 24, 2017. *Transfusion* 2018; 58(5): 1299–1306.

67. Farrugia A, Penrod J and Bult JM. The ethics of paid plasma donation: a plea for patient centeredness. *HEC Forum* 2015; 27: 417–429.

68. Allain J-P. Moving on from voluntary non-remunerated donors: who is the best blood donor. *Br J Haematol* 2011; 154: 763–769.

69. Pruett C, Vermeulen M, Zacharias P, et al. The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review. *Transfus Med Rev* 2015; 29: 35–44.

70. Selssam A. Pathogen inactivation of cellular blood products: an additional safety layer in transfusion medicine. *Front Med* 2017; 4: 219.

71. Marwaha N and Sachdev S. Current testing strategies for hepatitis C virus infection in blood donors and the way forward. *World J Gastroenterol* 2014; 20: 2948–2954.

72. Allain J-P, Goodrich RP, Owusu-Ofori AK, et al. Effect of plasmoidum inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomized controlled trial. *Lancet* 2016; 387: 1753–1761.

73. Butler EK and McCullough J. Pathogen reduction combined with rapid diagnostic tests to reduce the risk of transfusion-transmitted infections in Uganda. *Transfusion* 2018; 58: 854–861.

74. Ifland L, Bloch EM and Pitman JP. Funding blood safety in the 21st century. *Transfusion* 2018; 58: 105–112.

75. Ala F, Allain J-P, Bates I, et al. External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection. *PLoS Med* 2012; 9: e1001309.

76. Yazer MH, Cap AP and Spinella PC. How do I implement a whole blood program for massively bleeding patients. *Transfusion* 2018; 58: 622–628.

77. Yazer MH, Jackson B, Sperry JL, et al. Initial safety and feasibility of cold-stored uncrossmatched whole blood transfusion in civilian trauma patients. *J Trauma Acute Care Surg* 2016; 81: 21–26.

78. Yao K, Maruta T, Luman ET, et al. The SLMTA programme: transforming the laboratory landscape in developing countries. *Afr J Lab Med* 2014; 3: 194.

79. Eno LT, Asong T, Ngale E, et al. Driving hospital transformation with SLMTA in a regional hospital in Cameroon. *Afr J Lab Med* 2014; 3: 221.

80. Pirabán A, Guerrero WJ and Labadie N. Survey on blood supply chain management: models and methods. *Comput Oper Res* 2019; 112: 104756.

81. Scott JE and Scott CH. Drone delivery models for healthcare. *Int J Syst Sci* 2017; 2017: 3297–3304.

82. Glauser W. Blood-delivering drones saving lives in Africa and maybe soon in Canada. *Can Med Assoc J* 2018; 190: E88–E89.

83. Mahoha GA, Mwanda WO and Afulo OK. Autologous transfusion in surgical patients deployed to Nairobi. *East Afr Med J* 2001; 78: 546–567.

84. Sjoholm A, Alga A and von Schreeb J. A last resort when there is no blood: experiences and perceptions of intraoperative autotransfusion among medical doctors deployed to resource-limited settings. *World J Surg* 2020; 44: 4052–4059.

85. Spence RK and Erhard J. History of patient blood management. *Best Pract Res: Clin Anaesthesiol* 2013; 27: 11–15.

86. Sienko KH, Young MR, Kaufmann EE, et al. Global health design: clinical immersion, opportunity identification and
definition, and design experiences authors. Int J Eng Educ 2018; 34: 780–800.
87. Charles KS, Friday M, Lall D, et al. A university: led initiative to promote voluntary non-remunerated blood donation in a developing country. Transfus Apher Sci 2019; 58: 674–679.
88. Maghsudlu M. Keys to move to self-sufficiency in safe blood components based on voluntary blood donation. ISBT Sci 2017; 12: 202–206.
89. Flanagan P. Blood donation: incentives and inducements—where to draw the line? ISBT Sci 2019; 15: 19–22.
90. Sood R, Raykar N, Till B, et al. Walking blood banks: an immediate solution to rural India’s blood drought. Indian J Med Ethics 2018; 3: 134–137.
91. Chandler MH, Roberts M, Sawyer M, et al. The US military experience with fresh whole blood during the conflicts in Iraq and Afghanistan. Semin Cardiothorac Vasc Anesth 2012; 16: 153–159.
92. Bassett AK, Auten JD, Zieber TJ, et al. Early, prehospital activation of the walking blood bank based on mechanism of injury improves time to fresh whole blood transfusion. J Spec Oper Med 2016; 16: 5–8.